Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Classic Psychedelic or Neuroactive steroid or Sedative-Hypnotic

Use the filters below to narrow your results.

generic:
None (2)
brand:
None (78) · (none, never marketed) (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1) · Zulresso (1) · Zurzuvae (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · GABAA positive allosteric modulator (15) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (3) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · Contains LSA (2) · Contains mescaline (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2)
uses:
None (99) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1)
starting dose:
None (99) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)
preparations:
None (99) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
None (99) · 50 mg/d × 14 d (1) · N/A (never approved) (1) · Single 60-hour course (1)
routes:
None (98) · intranasal; rectal and IV reported. (1) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (3) · sublingual (1)
onset:
None (98) · 30–60 minutes (1) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Day 3 of dosing in trials; sustained through day 45 (1) · ~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (98) · 14-day course; effect persists after discontinuation in trials (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1) · Single infusion course (1)
halflife:
None (98) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~16-23 hours (1) · ~9 hours (terminal) (1)
bioavailability:
None (98) · 100% (IV) (1) · 70–90% (oral) (1) · Adequate (food-dependent, must take with fatty meal) (1) · Not formally characterized in humans. (1)
pregnancy:
None (98) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1) · Not established (1)
legal:
None (99) · Rx, Schedule IV (US) (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1) · Schedule I (United States) (1)

Showing below up to 102 results in range #1 to #102.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"